Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

2022242 citationsJournal Articlebronze Open Access

Authors

José Manuel Pérez-García · MedSIR (Spain)

Marta Vaz Batista · Hospital Prof. Dr. Fernando Fonseca

Patricia Cortez · Hospital Ruber Internacional

Manuel Ruíz‐Borrego · Hospital Universitario Virgen del Rocío

Juan Miguel Cejalvo · Hospital Clínico Universitario de Valencia

Juan de la Haba-Rodríguez · Instituto Maimónides de Investigación Biomédica de Córdoba

Laia Garrigós

Abstract

T-DXd showed intracranial activity with manageable toxicity and maintained the quality of life in pretreated HER2-positive ABC patients with stable, untreated, or progressing BMs. Further studies are needed to validate these results in larger cohorts.

Topics & Keywords

HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology Brain Metastases and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neuro-Oncology

Volume 25, Issue 1, pp. 157-166

DOI: 10.1093/neuonc/noac144

Field-Weighted Citation Impact: 24.30